Orbis Medicines

Private

#Immunology #Inflammation #Cardiometabolic

Danish biotech whose nGen platform discovers fully synthetic oral macrocyclic peptides (nCycles) that pair biologic-like target specificity with the convenience of an oral pill.

Company Info

Sector:Biotechnology / Drug Discovery Platform

Headquarters:Frederiksberg, Denmark

Founded:2023

Website:www.orbismedicines.com/

Funding Round:Series A

Total Funding:~$93M

Funding & Investor Relations

Notable Investors

Novo Holdings
Forbion

IPO Outlook / Plans

Private; no announced IPO timeline

Upcoming Milestones & Key Dates

2026-Q4

Corporate Milestone

Expansion of Copenhagen R&D site

Clinical Development Pipeline

nCycle oral macrocycle peptides

Target: Undisclosed intracellular and extracellular targets

Immunology and inflammation

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Leadership Team

Mikael Dolsten

Chair of the Board

Careers & Job Openings

See all open roles

Careers

Copenhagen, Denmark

Apply Now →